Timothy Mayer, Ph.D. | Chief Operating Officer
| Dr. Mayer has over 25 years and a broad range of experience in the biopharmaceutical industry, including antibody therapeutics, small molecule pharmaceuticals and laboratory cloning systems. As chief operating officer, he oversees corporate and business strategies, including licensing activities. In addition, he oversees intellectual property and manages all IP assets, directs prosecution on a global basis and conducts patentability and freedom-to-operate searches and evaluations. Previously, he was at a small ($1 billion) publicly-traded biotech company where he oversaw all intellectual property matters and assisted business development teams in various licensing transactions. In addition, he helped take the company public. Dr. Mayer also worked at an intellectual property law firm where he drafted and prosecuted biotech and pharmaceutical applications and conducted patentability and freedom-to-operate searches in all areas of biotechnology and small molecule chemistry. In addition, he worked for Life Technologies and Invitrogen where he developed cloning systems. Dr. Mayer received his PhD in Microbiology and Immunology from Penn State University College of Medicine and BS degrees in Microbiology and Biochemistry from California Polytechnic State University. |  |
• Michael Richman President & CEO  • Timothy Mayer, Ph.D. COO • Steven P. Cobourn, CPA CFO • Sol Langermann, Ph.D. CSO • Kevin Shaw General Counsel • Sourav Kundu, Ph.D. Senior Vice President, Development & Manufacturing • Udayan Guha, M.D., Ph.D. Senior Vice President, Clinical & Translational Development • Sebastien Maloveste, Ph.D. Senior Vice President, Business Development • Dallas Flies, Ph.D. Vice President, Discovery Research • Yvon Joseph Vice President, Quality Assurance |